Bicara Therapeutics' second quarter arrived as a handoff quarter, not a print quarter. The financial lines were unremarkable by clinical-stage standards - research and development up 85% year over year to $45.8M, net loss at $(55.4)M, GAAP basic and diluted loss per share of $(0.82) on 67.9M weighted-average shares. The story was structural: founder-CEO Claire Mazumdar announced a transition to Vice Chair and Strategic Advisor effective January 1, 2027, with President and Chief Operating Officer Ryan Cohlhepp taking the chief executive role; Chief Development Officer Tanya Green stepping up to Chief Operating Officer; Chief Corporate Affairs Officer Jenna Cohen moving to Chief Business Officer; Jenn Larson named Chief Financial Officer effective August 12, 2026; and Greg Shiferman arriving as Chief Legal Officer on August 31. Two new directors - former Day One Biopharmaceuticals chief executive Jeremy Bender and former Genentech Oncology business-unit head Christy Oliger - joined the board at the end of July, with founding director Kiran Mazumdar-Shaw retiring. None of that changes the Q2 numbers, and all of it points to the same thing: a company accelerating into a mid-2027 pivotal interim readout on its lead asset, ficerafusp alfa, in first-line recurrent or metastatic human papillomavirus-negative head and neck squamous cell carcinoma, where management expects substantial enrollment of the FORTIFI-HN01 study by year-end. The question the quarter answers is whether a clinical-stage, single-asset, $1.6B-market-cap equity is being run at a late-pivotal-trial cadence, with a board, an executive bench, and a roughly $497M cash position sufficient to take the company to the interim analysis without another raise, or whether the pivotal readout will land into a market that is still pricing the asset for what it might do rather than what the interim data show.